SARS‐CoV‐2 Evolution and Its Implications for RT‐PCR Diagnostic Performance
Journal of Medical Virology · 2026-06 · 98 (6)
DOI: 10.1002/jmv.71023 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Virology, online erschienen am 18.06.2026. Verfasst von Shubhangi Gupta und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biological Sciences and Engineering, Computational and Structural Biology Laboratory, Netaji Subhas University of Technology, Dwarka, N…. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19, Reverse Transcriptase Polymerase Chain Reaction, Evolution, Molecular. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Indian Council of Medical Research (ICMR).
Abstract (Originalsprache)
Mutations in SARS‐CoV‐2 primer/probe targets can compromise RT‐PCR sensitivity, leading to false negatives and undetected viral transmission. This study evaluated mutational landscapes of 20 primer/probe sets targeting E , N , Orf1b‐nsp14 , RdRp , and S genes using 1,35,852 high‐quality genomes across ten countries, five major variants, and three time periods (pre‐vaccination, post‐vaccination, and recent). Mutations were classified as high‐risk or moderate‐risk based on their positional susceptibility and mismatch burden. Mutation rate, impact risk, and population frequency within primer/probe targets was calculated along with their geographical‐, variant‐, and time‐dependent variations. Most E , N , RdRp , and S primer/probe targets showed higher and geographically variable mutation rates that increased with time. Variant‐wise analysis revealed that mutational accumulation in targets was significantly lower in early variants, that increased sharply with Delta and was most pronounced in Omicron (with its sub‐variants). High‐risk high‐frequency mutations were identified in targets of N ‐CCDC‐forward primer, N ‐NIH‐reverse primer, RdRp ‐Charité‐forward primer, S ‐Young‐forward primer, and S ‐Sigma (S1/S2)‐probes. Moderate‐risk high‐frequency mutations were observed in E ‐Charité‐forward primer, N ‐UCDC (N1)‐probe, and S ‐Chan‐probe. Mutation frequencies differed across countries due to circulating variants and also across time periods, with some mutations approaching fixation (≥ 95%) in the population. Orf1b‐nsp14 and selected N ‐gene targets like N‐Chan, N‐NIID, N‐UCDC (N2) sets remained mutation‐resilient, indicating their diagnostic reliability. A global and regional surveillance‐driven, threshold‐based strategy which involves periodic mutation monitoring every 6–12 months, consideration of primer/probe redesign when target mutations reach ≥ 10% frequency, and incorporating mutation‐resilient targets into multiplex assays is recommended to enhance SARS CoV‐2 RT‐PCR diagnostic accuracy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biological Sciences and Engineering, Computational and Structural Biology Laboratory, Netaji Subhas University of Technology, Dwarka, New Delhi, India.
ORCID-Profile: Shubhangi Gupta, Abhishek Chaudhary, Sonika Bhatnagar
Förderung
- Indian Council of Medical Research (ICMR)
Zitieren
APA
Gupta, S., Chaudhary, A., & Bhatnagar, S. (2026). SARS‐CoV‐2 Evolution and Its Implications for RT‐PCR Diagnostic Performance. Journal of Medical Virology, 98(6). https://doi.org/10.1002/jmv.71023
Vancouver
Gupta S, Chaudhary A, Bhatnagar S. SARS‐CoV‐2 Evolution and Its Implications for RT‐PCR Diagnostic Performance. Journal of Medical Virology. 2026;98(6). doi:10.1002/jmv.71023
BibTeX
@article{Gupta2026,
author = {Gupta, Shubhangi and Chaudhary, Abhishek and Bhatnagar, Sonika},
title = {SARS‐CoV‐2 Evolution and Its Implications for RT‐PCR Diagnostic Performance},
journal = {Journal of Medical Virology},
year = {2026},
volume = {98},
number = {6},
doi = {10.1002/jmv.71023}
}
EUVIMED